DexCom, Inc. $DXCM Holdings Cut by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 43.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,984 shares of the medical device company’s stock after selling 17,591 shares during the period. J. Safra Sarasin Holding AG’s holdings in DexCom were worth $1,547,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in DXCM. Vanguard Group Inc. boosted its position in DexCom by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock valued at $4,218,063,000 after purchasing an additional 866,506 shares during the period. Jennison Associates LLC lifted its stake in DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after buying an additional 994,300 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of DexCom by 3.4% during the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after acquiring an additional 358,617 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock worth $576,610,000 after acquiring an additional 3,410,858 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of DexCom in the 2nd quarter worth about $453,279,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

DXCM has been the subject of a number of analyst reports. Wall Street Zen lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. Weiss Ratings reissued a “sell (d+)” rating on shares of DexCom in a report on Monday, December 29th. BTIG Research lowered their target price on DexCom from $109.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Citigroup reaffirmed a “buy” rating and set a $77.00 target price (up previously from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Finally, Canaccord Genuity Group set a $99.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $86.30.

Insider Buying and Selling

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach acquired 18,200 shares of DexCom stock in a transaction dated Monday, November 10th. The shares were acquired at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the transaction, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. This represents a 5.81% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 7,866 shares of company stock valued at $448,177 over the last three months. Company insiders own 0.32% of the company’s stock.

DexCom Stock Performance

DXCM opened at $73.36 on Thursday. The business has a 50 day moving average price of $67.25 and a two-hundred day moving average price of $70.92. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The company has a market capitalization of $28.61 billion, a price-to-earnings ratio of 40.76, a price-to-earnings-growth ratio of 1.32 and a beta of 1.48. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.45 EPS. Research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.